February 8, 2019 Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
January 17, 2019 Critical Path Institute Celebrates Expanded Operations with Opening of European Headquarters C-Path in the EU will work to accelerate the development of new therapies through innovative methodologies for endorsement
January 8, 2019 Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial Resistance TUCSON, Ariz., January 8, 2019 — Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and M
January 4, 2019 At the IBD Biomarker Summit, Hosted by the Crohn’s & Colitis Foundation, C-Path Shares the Case for formation of an IBD Biomarker Consortium At the IBD Biomarkers Summit, hosted by the Crohn’s & Colitis Foundation on October 17-18, 2018, in Newark, N.J., Critical P
December 21, 2018 C-Path Board Member Paula Olsiewski Honored as AAAS 2018 Elected Fellow Paula Olsiewski, Ph.D., program director at the Alfred P. Sloan Foundation and Critical Path Institute board member, was named a 2
December 19, 2018 In Recognition of 10th Anniversary, Raymond Woosley and Janet Woodcock Address CPAD Consortium’s 2018 Annual Meeting and Regulatory Science Workshop At its 10th Annual Meeting and Regulatory Science Workshop, November 13, 2018, in Bethesda, MD, C-Path’s Critical Path for Alzhe
December 18, 2018 Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative Biomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Inst
December 17, 2018 CPTR Newsletter – December 2018 CPTR Newsletter – December 2018 In this issue: In the Spotlight: TB-ReFLECT Manuscript Published Updates to the TB
December 12, 2018 U.S. Food and Drug Administration Awards Contract to Critical Path Institute for Kidney Transplant Database Patient-level data will inform the creation of drug development tools and speed development of new immunosuppressive treatments TU
